Dow Jones
38.742,18 +66,50 (+0,17%) Nasdaq
16.269,46 +113,14 (+0,70%) Nikkei 225
38.236,07 -38,03 (-0,10%) EUR/USD
1,0777 +0,0010 (+0,10%) Bitcoin EUR
58.890,91 -852,61 (-1,43%) CMC Crypto 200
1.369,11 +56,49 (+4,30%)
GILD May 2024 66.000 call
| Chiusura precedente | 0,8700 |
| Aperto | 0,8600 |
| Denaro | 0,7300 |
| Lettera | 0,8500 |
| Prezzo d'esercizio | 66,00 |
| Scadenza | 2024-05-31 |
| Min-Max giorno | 0,7300 - 1,0000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 11 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr
